Back to top

Image: Bigstock

Integra (IART) Up 9.9% Since Last Earnings Report: Can It Continue?

Read MoreHide Full Article

It has been about a month since the last earnings report for Integra LifeSciences (IART - Free Report) . Shares have added about 9.9% in that time frame, outperforming the S&P 500.

Will the recent positive trend continue leading up to its next earnings release, or is Integra due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its latest earnings report in order to get a better handle on the important catalysts.

Integra's Q3 Earnings Top Estimates, Revenues Miss

Integra LifeSciences Holdings Corporation reported adjusted earnings per share of 59 cents for the third quarter of 2026, beating the consensus estimate by 5.4%. The metric increased 9.3% year over year, primarily reflecting revenue growth and lower operating expenses.

On a GAAP basis, earnings were 19 cents per share, compared to a loss of 7 cents in the year-ago period. The adjustment excludes certain charges, including structural optimization, acquisition and integration-related expenses, EU Medical Device Regulation charges, the Braintree manufacturing transition and Cincinnati flood-related costs, among others.

Revenues increased 2.3% year over year to $411.2 million, missing the Zacks Consensus Estimate by 0.8%. Organically, revenues grew 2.5%.

Integra's Specialty Surgery Sales Rise

Specialty Surgery revenues totaled $304.1 million, increasing 3.9% year over year on a reported basis and 4.2% organically, despite an approximately $7 million Cincinnati-related revenue impact. Neurosurgery sales grew 6.5% organically, supported by strong demand for CereLink, Certas Plus, BactiSeal, DuraSeal and cranial perforators. International Specialty Surgery revenues increased 7.8%, benefiting from improved product availability and strength across several geographies.

Meanwhile, Instruments revenues declined 0.9% organically, primarily due to order timing. ENT sales decreased 1.1% organically, reflecting a low-single-digit decline in sinus balloon products.

IART's Tissue Reconstruction Sales Decline

Tissue Reconstruction revenues amounted to $107.1 million, declining 2.2% year over year on both reported and organic bases. Wound Reconstruction sales declined in the low single digits. Strong growth in DuraSorb and PriMatrix was more than offset by weakness in MicroMatrix and Integra Skin. Management highlighted competitive pressures and slower-than-anticipated market-share recovery across certain products.

Corporate Partnerships, previously known as Private Label, remained approximately flat year over year. Management expects the underlying Tissue Reconstruction business to remain flat in 2027, with the planned SurgiMend relaunch contributing incremental growth.

IART’s Margin Performance

In the reported quarter, gross profit totaled $209.9 million, up 1.4% year over year. The gross margin contracted 50 basis points (bps) to 51% on a 3.2% increase in the cost of goods sold.

Selling, general and administrative expenses decreased 2.2% to $165.3 million in the quarter under review, while research and development expenses fell 2.5% to $21.9 million. Overall, the adjusted operating profit was $69.5 million, up 3.5% year over year. The adjusted operating margin expanded 20 bps to 16.9%.

IART's Financial Position Strengthens

Integra exited the third quarter of 2026 with approximately $252.3 million in cash and cash equivalents compared with $235 million at the end of the fourth quarter of 2025.

Cumulative net cash provided by operating activities at the end of the third quarter of 2026 was $128.6 million compared with $38.6 million a year ago.

Following quarter-end, Integra completed a $2.1 billion refinancing, extending debt maturities and improving financial flexibility. However, the transaction is expected to increase interest expenses.

Integra Provides Q4 and 2026 Guidance

For the fourth quarter of 2026, Integra expects revenues between $413 million and $433 million, indicating a reported year-over-year decline of 5.2% to 0.5%. Adjusted earnings per share is projected between 61 cents and 71 cents.

For full-year 2026, revenues are expected between $1.634 billion and $1.654 billion, representing reported growth ranging from a 0.1% decline to a 1.2% increase. Adjusted earnings per share is projected between $2.30 and $2.40. The company continues to anticipate operating cash flow of approximately $190 million to $200 million for the full year.

Management expects the Cincinnati disruption to reduce fourth-quarter revenues by approximately $15 million to $20 million, with full manufacturing operations anticipated to resume during the second quarter of 2027. The updated outlook reflects continued manufacturing challenges and more measured expectations for Tissue Reconstruction, partially balanced by strength in Specialty Surgery and ongoing cost-reduction initiatives.

How Have Estimates Been Moving Since Then?

Since the earnings release, investors have witnessed a downward trend in fresh estimates.

The consensus estimate has shifted -9.87% due to these changes.

VGM Scores

Currently, Integra has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with a D. Charting a somewhat similar path, the stock was allocated a grade of C on the value side, putting it in the middle 20% for this investment strategy.

Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.

Outlook

Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. It's no surprise Integra has a Zacks Rank #5 (Strong Sell). We expect a below average return from the stock in the next few months.

Published in